Astellas Pharma today announced that the US Food and Drug Administration (FDA) has approved VYLOY (zolbetuximab-clzb) in ...

Acute fatty liver of pregnancy (AFLP) is a rare obstetric complication, and despite improvements in recognition and management over recent decades, it still carries a high risk of maternal and fetal ...

If these agents are not effective, clinicians might turn to more-potent antiemetics, such as the dopamine antagonist metoclopramide. To assess the association between metoclopramide use during ...

The novel co-occurrence of JAK2, CALR & MPL mutations in a patient with myelofibrosis challenges previous knowledge that ...

VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...

Purpose: Data collected from the Food and Drug Administration (FDA) under the Freedom of Information Act are presented to help clinicians understand the data prompting the black-box warning for ...